

Katsutoshi Oda

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3577719/publications.pdf>

Version: 2024-02-01

113
papers

3,930
citations

172207

29
h-index

133063

59
g-index

117
all docs

117
docs citations

117
times ranked

5694
citing authors

#	ARTICLE	IF	CITATIONS
1	p53AIP1, a Potential Mediator of p53-Dependent Apoptosis, and Its Regulation by Ser-46-Phosphorylated p53. <i>Cell</i> , 2000, 102, 849-862.	13.5	1,095
2	High Frequency of Coexistent Mutations of PIK3CA and PTEN Genes in Endometrial Carcinoma. <i>Cancer Research</i> , 2005, 65, 10669-10673.	0.4	432
3	PIK3CA Cooperates with Other Phosphatidylinositol 3-Kinase Pathway Mutations to Effect Oncogenic Transformation. <i>Cancer Research</i> , 2008, 68, 8127-8136.	0.4	159
4	Genomics to immunotherapy of ovarian clear cell carcinoma: Unique opportunities for management. <i>Gynecologic Oncology</i> , 2018, 151, 381-389.	0.6	99
5	Oral vaccination against HPV E7 for treatment of cervical intraepithelial neoplasia grade 3 (CIN3) elicits E7-specific mucosal immunity in the cervix of CIN3 patients. <i>Vaccine</i> , 2014, 32, 6233-6239.	1.7	87
6	Uterine adenomyosis is an oligoclonal disorder associated with KRAS mutations. <i>Nature Communications</i> , 2019, 10, 5785.	5.8	82
7	Oral immunization with a <i>Lactobacillus casei</i> vaccine expressing human papillomavirus (HPV) type 16 E7 is an effective strategy to induce mucosal cytotoxic lymphocytes against HPV16 E7. <i>Vaccine</i> , 2010, 28, 2810-2817.	1.7	79
8	The anti-malarial chloroquine suppresses proliferation and overcomes cisplatin resistance of endometrial cancer cells via autophagy inhibition. <i>Gynecologic Oncology</i> , 2015, 137, 538-545.	0.6	67
9	Genotype-Dependent Efficacy of a Dual PI3K/mTOR Inhibitor, NVP-BEZ235, and an mTOR Inhibitor, RAD001, in Endometrial Carcinomas. <i>PLoS ONE</i> , 2012, 7, e37431.	1.1	67
10	Matrix Metalloproteinase (MMP)-9 in Cancer-Associated Fibroblasts (CAFs) Is Suppressed by Omega-3 Polyunsaturated Fatty Acids In Vitro and In Vivo. <i>PLoS ONE</i> , 2014, 9, e89605.	1.1	58
11	Anti-tumor activity of olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, in cultured endometrial carcinoma cells. <i>BMC Cancer</i> , 2014, 14, 179.	1.1	55
12	PI3K/mTOR pathway inhibition overcomes radioresistance via suppression of the HIF1- α /VEGF pathway in endometrial cancer. <i>Gynecologic Oncology</i> , 2015, 138, 174-180.	0.6	52
13	Oncogenic histone methyltransferase EZH2: A novel prognostic marker with therapeutic potential in endometrial cancer. <i>Oncotarget</i> , 2017, 8, 40402-40411.	0.8	52
14	Spheroid cancer stem cells display reprogrammed metabolism and obtain energy by actively running the tricarboxylic acid (TCA) cycle. <i>Oncotarget</i> , 2016, 7, 33297-33305.	0.8	52
15	Clinical practice guidance for next-generation sequencing in cancer diagnosis and treatment (edition) Tj ETQq1 1 0,784314 rgBT /Ove	1.0	49
16	Comprehensive assay for the molecular profiling of cancer by target enrichment from formalin-fixed paraffin-embedded specimens. <i>Cancer Science</i> , 2019, 110, 1464-1479.	1.7	48
17	Cancer-associated fibroblast suppresses killing activity of natural killer cells through downregulation of poliovirus receptor (PVR/CD155), a ligand of activating NK receptor. <i>International Journal of Oncology</i> , 2016, 49, 1297-1304.	1.4	47
18	Activation of Nrf2 might reduce oxidative stress in human granulosa cells. <i>Molecular and Cellular Endocrinology</i> , 2018, 470, 96-104.	1.6	46

#	ARTICLE	IF	CITATIONS
19	Systemic delivery of siRNA by actively targeted polyion complex micelles for silencing the E6 and E7 human papillomavirus oncogenes. <i>Journal of Controlled Release</i> , 2016, 231, 29-37.	4.8	42
20	Antitumor Activity and Induction of TP53-Dependent Apoptosis toward Ovarian Clear Cell Adenocarcinoma by the Dual PI3K/mTOR Inhibitor DS-7423. <i>PLoS ONE</i> , 2014, 9, e87220.	1.1	40
21	Integrated Copy Number and Expression Analysis Identifies Profiles of Whole-Arm Chromosomal Alterations and Subgroups with Favorable Outcome in Ovarian Clear Cell Carcinomas. <i>PLoS ONE</i> , 2015, 10, e0128066.	1.1	38
22	Activation of Nrf2/Keap1 pathway by oral Dimethylfumarate administration alleviates oxidative stress and age-associated infertility might be delayed in the mouse ovary. <i>Reproductive Biology and Endocrinology</i> , 2019, 17, 23.	1.4	37
23	Significance of survivin as a prognostic factor and a therapeutic target in endometrial cancer. <i>Gynecologic Oncology</i> , 2016, 141, 564-569.	0.6	35
24	MDM2 is a potential therapeutic target and prognostic factor for ovarian clear cell carcinomas with wild type TP53. <i>Oncotarget</i> , 2016, 7, 75328-75338.	0.8	33
25	Interleukin-17 is associated with expression of programmed cell death 1 ligand 1 in ovarian carcinoma. <i>Cancer Science</i> , 2019, 110, 3068-3078.	1.7	32
26	Putative tumor suppression function of SIRT6 in endometrial cancer. <i>FEBS Letters</i> , 2015, 589, 2274-2281.	1.3	31
27	Autophagy inhibition augments resveratrol-induced apoptosis in Ishikawa endometrial cancer cells. <i>Oncology Letters</i> , 2016, 12, 2560-2566.	0.8	31
28	Kaempferol, a natural dietary flavonoid, suppresses 17 β -estradiol-induced survivin expression and causes apoptotic cell death in endometrial cancer. <i>Oncology Letters</i> , 2018, 16, 6195-6201.	0.8	31
29	Prognostic importance of CDK4/6-specific activity as a predictive marker for recurrence in patients with endometrial cancer, with or without adjuvant chemotherapy. <i>British Journal of Cancer</i> , 2015, 113, 1477-1483.	2.9	30
30	Automated system for diagnosing endometrial cancer by adopting deep-learning technology in hysteroscopy. <i>PLoS ONE</i> , 2021, 16, e0248526.	1.1	30
31	The Prevalence Of Cervical Regulatory T Cells in HPV-Related Cervical Intraepithelial Neoplasia (CIN) Correlates Inversely with Spontaneous Regression of CIN. <i>American Journal of Reproductive Immunology</i> , 2013, 69, 134-141.	1.2	29
32	Inhibition of endoplasmic reticulum (ER) stress sensors sensitizes cancer stem-like cells to ER stress-mediated apoptosis. <i>Oncotarget</i> , 2016, 7, 51854-51864.	0.8	29
33	Establishment and Molecular Phenotyping of Organoids from the Squamocolumnar Junction Region of the Uterine Cervix. <i>Cancers</i> , 2020, 12, 694.	1.7	26
34	Histone methyltransferase SMYD2 selective inhibitor LLY-507 in combination with poly ADP ribose polymerase inhibitor has therapeutic potential against high-grade serous ovarian carcinomas. <i>Biochemical and Biophysical Research Communications</i> , 2019, 513, 340-346.	1.0	24
35	Clinical significance of Gremlin 1 in cervical cancer and its effects on cancer stem cell maintenance. <i>Oncology Reports</i> , 2016, 35, 391-397.	1.2	23
36	Phase II basket trial of perifosine monotherapy for recurrent gynecologic cancer with or without PIK3CA mutations. <i>Investigational New Drugs</i> , 2017, 35, 800-812.	1.2	23

#	ARTICLE	IF	CITATIONS
37	Aromatase inhibitor anastrozole as a second-line hormonal treatment to a recurrent low-grade endometrial stromal sarcoma: a case report. <i>Medical Oncology</i> , 2011, 28, 771-774.	1.2	22
38	Development of ovarian cancer after excision of endometrioma. <i>Fertility and Sterility</i> , 2016, 106, 1432-1437.e2.	0.5	22
39	The frequency of neoantigens per somatic mutation rather than overall mutational load or number of predicted neoantigens per se is a prognostic factor in ovarian clear cell carcinoma. <i>Oncolmmunology</i> , 2017, 6, e1338996.	2.1	22
40	Modification of the Tumor Microenvironment in KRAS or c-MYC-Induced Ovarian Cancer-Associated Peritonitis. <i>PLoS ONE</i> , 2016, 11, e0160330.	1.1	21
41	Update on rare epithelial ovarian cancers: based on the Rare Ovarian Tumors Young Investigator Conference. <i>Journal of Gynecologic Oncology</i> , 2017, 28, e54.	1.0	20
42	Antitumor activity of a combination of dual PI3K/mTOR inhibitor SAR245409 and selective MEK1/2 inhibitor pimasertib in endometrial carcinomas. <i>Gynecologic Oncology</i> , 2015, 138, 323-331.	0.6	19
43	Sequential effects of the proteasome inhibitor bortezomib and chemotherapeutic agents in uterine cervical cancer cell lines. <i>Oncology Reports</i> , 2013, 29, 51-57.	1.2	18
44	Expression of Par3 polarity protein correlates with poor prognosis in ovarian cancer. <i>BMC Cancer</i> , 2016, 16, 897.	1.1	18
45	Radical hysterectomy with or without para-aortic lymphadenectomy for patients with stage IB2, IIA2, and IIB cervical cancer: outcomes for a series of 308 patients. <i>International Journal of Clinical Oncology</i> , 2016, 21, 359-366.	1.0	18
46	Anti-Tumor Effect of Inhibition of DNA Damage Response Proteins, ATM and ATR, in Endometrial Cancer Cells. <i>Cancers</i> , 2019, 11, 1913.	1.7	18
47	Synergistic antitumor effects of combination PI3K/mTOR and MEK inhibition (SAR245409 and pimasertib) in mucinous ovarian carcinoma cells by fluorescence resonance energy transfer imaging. <i>Oncotarget</i> , 2016, 7, 29577-29591.	0.8	18
48	Minimization of curative surgery for treatment of early cervical cancer: a review. <i>Japanese Journal of Clinical Oncology</i> , 2015, 45, 611-616.	0.6	17
49	Characterization of TP53 and PI3K signaling pathways as molecular targets in gynecologic malignancies. <i>Journal of Obstetrics and Gynaecology Research</i> , 2016, 42, 757-762.	0.6	17
50	Decreased expression of the plasminogen activator inhibitor type 1 is involved in degradation of extracellular matrix surrounding cervical cancer stem cells. <i>International Journal of Oncology</i> , 2016, 48, 829-835.	1.4	17
51	Detachment from the primary site and suspension in ascites as the initial step in metabolic reprogramming and metastasis to the omentum in ovarian cancer. <i>Oncology Letters</i> , 2017, 15, 1357-1361.	0.8	17
52	Therapeutic significance of targeting survivin in cervical cancer and possibility of combination therapy with TRAIL. <i>Oncotarget</i> , 2018, 9, 13451-13461.	0.8	17
53	STAT3 activity regulates sensitivity to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in cervical cancer cells. <i>International Journal of Oncology</i> , 2016, 49, 2155-2162.	1.4	16
54	The oncogene KRAS promotes cancer cell dissemination by stabilizing spheroid formation via the MEK pathway. <i>BMC Cancer</i> , 2018, 18, 1201.	1.1	16

#	ARTICLE	IF	CITATIONS
55	The histone methyltransferase SMYD2 is a novel therapeutic target for the induction of apoptosis in ovarian clear cell carcinoma cells. <i>Oncology Letters</i> , 2020, 20, 1-1.	0.8	15
56	Cyclin D1 harboring the T286I mutation promotes oncogenic activation in endometrial cancer. <i>Oncology Reports</i> , 2013, 30, 584-588.	1.2	14
57	Cyodiagnostic Problems in Uterine Sarcoma. <i>Acta Cytologica</i> , 2004, 48, 181-186.	0.7	13
58	Enhanced efficacy against cervical carcinomas through polymeric micelles physically incorporating the proteasome inhibitor MG 132. <i>Cancer Science</i> , 2016, 107, 773-781.	1.7	13
59	The histone methyltransferase WHSC1 is regulated by EZH2 and is important for ovarian clear cell carcinoma cell proliferation. <i>BMC Cancer</i> , 2019, 19, 455.	1.1	13
60	Genome-Wide Single Nucleotide Polymorphism Arrays as a Diagnostic Tool in Patients With Synchronous Endometrial and Ovarian Cancer. <i>International Journal of Gynecological Cancer</i> , 2012, 22, 725-731.	1.2	12
61	Bevacizumab-Related Microvascular Angina and Its Management with Nicorandil. <i>International Heart Journal</i> , 2017, 58, 803-805.	0.5	12
62	Regeneration of cervical reserve cell-like cells from human induced pluripotent stem cells (iPSCs): A new approach to finding targets for cervical cancer stem cell treatment. <i>Oncotarget</i> , 2017, 8, 40935-40945.	0.8	12
63	Multistate Markov Model to Predict the Prognosis of High-Risk Human Papillomavirus-Related Cervical Lesions. <i>Cancers</i> , 2020, 12, 270.	1.7	12
64	mTOR Signaling in Endometrial Cancer: From a Molecular and Therapeutic Point of View. <i>Current Obstetrics and Gynecology Reports</i> , 2015, 4, 1-10.	0.3	11
65	A Placebo-Controlled, Double-Blind Randomized (Phase IIB) Trial of Oral Administration with HPV16 E7-Expressing <i>Lactobacillus</i> , GLBL101c, for the Treatment of Cervical Intraepithelial Neoplasia Grade 2 (CIN2). <i>Vaccines</i> , 2021, 9, 329.	2.1	11
66	The metabolic stress-activated checkpoint LKB1-MARK3 axis acts as a tumor suppressor in high-grade serous ovarian carcinoma. <i>Communications Biology</i> , 2022, 5, 39.	2.0	11
67	CCAR2 negatively regulates nuclear receptor LXR α by competing with SIRT1 deacetylase. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2015, 149, 80-88.	1.2	10
68	Measurement of endometrial thickness by transvaginal ultrasonography to predict pathological response to medroxyprogesterone acetate in patients with grade 1 endometrioid adenocarcinoma. <i>Molecular and Clinical Oncology</i> , 2016, 4, 492-496.	0.4	10
69	A case of lymphangiomyomatosis associated with endometrial cancer and severe systemic lupus erythematosus. <i>BMC Cancer</i> , 2016, 16, 390.	1.1	10
70	Low uptake of fluorodeoxyglucose in positron emission tomography/computed tomography in ovarian clear cell carcinoma may reflect glutaminolysis of its cancer stem cell-like properties. <i>Oncology Reports</i> , 2017, 37, 1883-1888.	1.2	10
71	Recent advances in targeting DNA repair pathways for the treatment of ovarian cancer and their clinical relevance. <i>International Journal of Clinical Oncology</i> , 2017, 22, 611-618.	1.0	10
72	Targeting glutamine metabolism and the focal adhesion kinase additively inhibits the mammalian target of the rapamycin pathway in spheroid cancer stem-like properties of ovarian clear cell carcinoma in vitro. <i>International Journal of Oncology</i> , 2017, 50, 1431-1438.	1.4	10

#	ARTICLE	IF	CITATIONS
73	Enhanced antitumor activity of combined lipid bubble ultrasound and anticancer drugs in gynecological cervical cancers. <i>Cancer Science</i> , 2021, 112, 2493-2503.	1.7	10
74	Xanthogranulomatous inflammation of the perimetrium with infiltration into the uterine myometrium in a postmenopausal woman: a case report. <i>BMC Women's Health</i> , 2014, 14, 82.	0.8	9
75	HAND2-mediated proteolysis negatively regulates the function of estrogen receptor β . <i>Molecular Medicine Reports</i> , 2015, 12, 5538-5544.	1.1	9
76	Intraperitoneal neutrophils activated by KRAS-induced ovarian cancer exert antitumor effects by modulating adaptive immunity. <i>International Journal of Oncology</i> , 2018, 53, 1580-1590.	1.4	9
77	Anti-tumor activity of dual inhibition of phosphatidylinositol 3-kinase and MDM2 against clear cell ovarian carcinoma. <i>Gynecologic Oncology</i> , 2019, 155, 331-339.	0.6	9
78	Usefulness of cell-free and concentrated ascites reinfusion therapy in the therapeutic management of advanced ovarian cancer patients with massive ascites. <i>International Journal of Clinical Oncology</i> , 2019, 24, 420-427.	1.0	9
79	Comprehensive immunohistochemical analysis of the gastrointestinal and allergic phenotypes of 139 ovarian mucinous cystadenomas. <i>Human Pathology</i> , 2021, 109, 21-30.	1.1	9
80	A low preoperative albumin-to-globulin ratio is a negative prognostic factor in patients with surgically treated cervical cancer. <i>International Journal of Clinical Oncology</i> , 2021, 26, 980-985.	1.0	9
81	Genomic profiling of multiple primary cancers including synchronous lung adenocarcinoma and bilateral malignant mesotheliomas: Identification of a novel <i>BAP1</i> germline variant. <i>Pathology International</i> , 2020, 70, 775-780.	0.6	8
82	Non-diethylstilbestrol exposed vaginal clear cell adenocarcinoma has a common molecular profile with ovarian clear cell adenocarcinoma: A case report. <i>Gynecologic Oncology Reports</i> , 2014, 10, 49-52.	0.3	7
83	The Emerging Role of FOXL2 in Regulating the Transcriptional Activation Function of Estrogen Receptor β : An Insight Into Ovarian Folliculogenesis. <i>Reproductive Sciences</i> , 2017, 24, 133-141.	1.1	7
84	Mixed endometrioid and clear cell carcinoma arising from laparoscopic trocar site endometriosis. <i>Journal of Obstetrics and Gynaecology Research</i> , 2019, 45, 1613-1618.	0.6	7
85	Effect of murine double-strand break repair 2 inhibitors in preclinical models of advanced clear cell carcinomas originating from ovaries and kidneys. <i>Cancer Science</i> , 2020, 111, 3824-3834.	1.7	7
86	Characterization of Novel Transcripts of Human Papillomavirus Type 16 Using Cap Analysis Gene Expression Technology. <i>Journal of Virology</i> , 2015, 89, 2448-2452.	1.5	6
87	Risk of endometrial cancer in patients with a preoperative diagnosis of atypical endometrial hyperplasia treated with total laparoscopic hysterectomy. <i>Gynecology and Minimally Invasive Therapy</i> , 2016, 5, 69-73.	0.2	6
88	On-chip immunofluorescence analysis of single cervical cells using an electroactive microwell array with barrier for cervical screening. <i>Biomicrofluidics</i> , 2019, 13, 044107.	1.2	6
89	Gynecological Cancers Translational, Research Implementation, and Harmonization: Gynecologic Cancer InterGroup Consensus and Still Open Questions. <i>Cells</i> , 2019, 8, 200.	1.8	6
90	Histone arginine methyltransferase CARM1 selective inhibitor TP-064 induces apoptosis in endometrial cancer. <i>Biochemical and Biophysical Research Communications</i> , 2022, 601, 123-128.	1.0	6

#	ARTICLE	IF	CITATIONS
91	HPV-16 impairs the subcellular distribution and levels of expression of protein phosphatase 1 ^β in cervical malignancy. <i>BMC Cancer</i> , 2015, 15, 230.	1.1	5
92	Vaginal cancer possibly caused by pessary and immunocompromised condition: Multiple risk factors may influence vaginal cancer development. <i>Journal of Obstetrics and Gynaecology Research</i> , 2016, 42, 748-751.	0.6	5
93	Spinal solitary fibrous tumor of the neck: Next-generation sequencing-based analysis of genomic aberrations. <i>Auris Nasus Larynx</i> , 2020, 47, 1058-1063.	0.5	5
94	Reconstructed uterine length is critical for the prevention of cervical stenosis following abdominal trachelectomy in cervical cancer patients. <i>Journal of Obstetrics and Gynaecology Research</i> , 2020, 46, 328-336.	0.6	5
95	A case of successful detection of disseminated gastrointestinal stromal tumors by ascites smear cytology using cell block preparation with <sc>DOG</sc>1 immunostaining. <i>Diagnostic Cytopathology</i> , 2016, 44, 137-140.	0.5	4
96	Intracellular signaling entropy can be a biomarker for predicting the development of cervical intraepithelial neoplasia. <i>PLoS ONE</i> , 2017, 12, e0176353.	1.1	4
97	Desensitization strategy for hypersensitivity reactions to carboplatin in five patients with gynecological cancer. <i>Journal of Obstetrics and Gynaecology Research</i> , 2020, 46, 2298-2304.	0.6	4
98	Phase II study of niraparib in recurrent or persistent rare fraction of gynecologic malignancies with homologous recombination deficiency (JGOG2052). <i>Journal of Gynecologic Oncology</i> , 2022, 33, .	1.0	4
99	Differential expression of human papillomavirus 16-, 18-, 52-, and 58-derived transcripts in cervical intraepithelial neoplasia. <i>Virology Journal</i> , 2020, 17, 32.	1.4	3
100	Usefulness of biopsy by office hysteroscopy for endometrial cancer: A case report. <i>Molecular and Clinical Oncology</i> , 2020, 13, 141-145.	0.4	3
101	Low-grade endometrial stromal sarcoma developing in a postmenopausal woman under toremifene treatment for breast cancer. <i>Journal of Obstetrics and Gynaecology Research</i> , 2013, 39, 424-429.	0.6	2
102	Huge pyogenic cervical cyst with endometriosis, developing 13 years after myomectomy at the lower uterine segment: a case report. <i>BMC Women's Health</i> , 2014, 14, 104.	0.8	2
103	Effect of primary prophylaxis with pegfilgrastim in endometrial cancer patients treated with doxorubicin and cisplatin. <i>Taiwanese Journal of Obstetrics and Gynecology</i> , 2022, 61, 265-269.	0.5	2
104	Use of Cap Analysis Gene Expression to detect human papillomavirus promoter activity patterns at different disease stages. <i>Scientific Reports</i> , 2020, 10, 17991.	1.6	1
105	Effect of weekly administration of bevacizumab, gemcitabine, and oxaliplatin in patients with heavily pretreated ovarian cancer.. <i>Journal of Clinical Oncology</i> , 2012, 30, 5037-5037.	0.8	1
106	NGS-based molecular profiling (a multi-center collaborative, observation study in Japan) highlights pathogenic variants of DNA-repair genes in advanced or recurrent endometrial cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, e13510-e13510.	0.8	1
107	Genetic diagnosis of pseudomyxoma peritonei originating from mucinous borderline tumor inside an ovarian teratoma. <i>BMC Medical Genomics</i> , 2022, 15, 51.	0.7	1
108	Recurrent cervical cancer with <sc>PD-L1</sc> amplification treated with nivolumab: A case enrolled in the <sc>BELIEVE</sc> trial. <i>Journal of Obstetrics and Gynaecology Research</i> , 2022, , .	0.6	1

#	ARTICLE	IF	CITATIONS
109	OUP accepted manuscript. Japanese Journal of Clinical Oncology, 2022, , .	0.6	1
110	Perspectives on targeting the phosphatidylinositol 3-kinase pathway for personalized medicine in endometrial and ovarian cancers. Personalized Medicine Universe, 2016, 5, 3-7.	0.1	0
111	Development of endometrioma after cervical conization. Gynecological Endocrinology, 2018, 34, 341-344.	0.7	0
112	Cancer Genomic Profiling of Gynecological Malignancies by Todai OncoPanel, a Twin DNA and RNA Panel. Current Human Cell Research and Applications, 2021, , 27-39.	0.1	0
113	Combination chemotherapy with temsirolimus and trabectedin in patients with heavily pretreated clear cell carcinoma of the ovary.. Journal of Clinical Oncology, 2013, 31, e16519-e16519.	0.8	0